title: Small airway impairment in moderate to severe asthmatics without significant proximal airway obstruction.
abstract: Asthma is a disease characterized by inflammation which affects both proximal and distal airways. We evaluated the prevalence of small airway obstruction (SAO) in a group of clinically stable asthmatics with both normal forced expiratory volume in the first second (FEV1) and normal FEV1/forced vital capacity (FVC) and treated with an association of inhaled corticosteroids (ICSs) and long acting β2-agonists (LABAs). Clinical evaluation included the measurement of dyspnea, asthma control test and drug compliance. The prevalence of SAO was estimated by spirometry and plethysmography and defined by the presence of one or more of the following criteria: functional residual capacity (FRC) > 120% predicted (pred), residual volume (RV) > pred + 1.64 residual standard deviation (RSD), RV/total lung capacity (TLC) > pred + 1.64 RSD, forced expiratory flow (FEF)25-75% < pred - 1.64 RSD, FEF50% < pred - 1.64 RSD, slow vital capacity (SVC) - FVC > 10%. Among the 441 patients who were included, 222 had normal FEV1 and FEV1/FVC. At least one criteria of SAO was found in 115 (52%) mainly lung hyperinflation (39% based on high FRC, RV or RV/TLC) and more rarely distal airflow limitation (15% based on FEF25-75% or FEF50%) or expiratory trapping (10% based on increased SVC - FVC). In the patients with only SAO (no PAO), there was no relationship between SAO, asthma history and the scores of dyspnea, asthma control or drug compliance. These results suggest that in asthmatics with normal FEV1 and FEV1/FVC, treated with ICSs and LABAs, SAO is found in more than half of the patients indicating that the routinely used lung function tests can underestimate dysfunctions occurring in the small airways.
authors.affiliation: Clinique des Maladies Respiratoires, Hôpital Calmette, CHRU Lille et Université Lille Nord de France, 59037 Lille Cedex, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Perez
authors.forename: Pascal
authors.initials: P
authors.lastname: Chanez
authors.forename: Daniel
authors.initials: D
authors.lastname: Dusser
authors.forename: Philippe
authors.initials: P
authors.lastname: Devillier
mesh_terms: D058666:Adrenergic beta-2 Receptor Agonists / Q000627:therapeutic use; D000328:Adult; D000403:Airway Resistance / Q000502:physiology; D001249:Asthma / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D003430:Cross-Sectional Studies; D004359:Drug Therapy, Combination; D004417:Dyspnea / Q000209:etiology / Q000503:physiopathology; D005260:Female; D005541:Forced Expiratory Volume / Q000502:physiology; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D010991:Plethysmography / Q000379:methods; D029424:Pulmonary Disease, Chronic Obstructive / Q000209:etiology; D013147:Spirometry / Q000379:methods; D014109:Total Lung Capacity / Q000502:physiology*; D014797:Vital Capacity / Q000502:physiology
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D005938:Glucocorticoids
keywords: Asthma; Hyperinflation; Small airways